Company Description
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD).
It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the α4β7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn’s disease).
The company is developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-α4β7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies.
In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004; SPY130, a combination of anti-α4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs.
The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023.
The company was incorporated in 2013 and is based in Waltham, Massachusetts.
| Country | United States |
| Founded | 2013 |
| IPO Date | Apr 7, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 65 |
| CEO | Cameron Turtle |
Contact Details
Address: 221 Crescent Street, Building 23 Waltham, Massachusetts 02453 United States | |
| Phone | 617 651 5940 |
| Website | spyre.com |
Stock Details
| Ticker Symbol | SYRE |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001636282 |
| CUSIP Number | 00773J202 |
| ISIN Number | US00773J2024 |
| Employer ID | 46-4312787 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Cameron Turtle DPHIL, Ph.D. | Chief Executive Officer and Director |
| Scott L. Burrows | Chief Financial Officer |
| Dr. Sheldon Sloan M.B.E., M.D. | Chief Medical Officer |
| Dr. Janet Gunzner-Toste M.B.A., Ph.D. | Senior Vice President of Operations |
| Brian Connolly | Chief Technical Officer |
| Eric McIntyre | Vice President of Finance and Investor Relations |
| Heidy Abreu King-Jones J.D., L.L.M. | Chief Legal Officer and Corporate Secretary |
| James Myers | Vice President of Quality and Compliance |
| Dr. Justin LaFountaine Ph.D. | Senior Vice President of Corporate Development |
| Melissa Cooper | Senior Vice President of People |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 13, 2025 | EFFECT | Notice of Effectiveness |
| Mar 7, 2025 | EFFECT | Notice of Effectiveness |
| Mar 7, 2025 | POS AM | Post-Effective amendments for registration statement |
| Mar 6, 2025 | 8-K | Current Report |
| Feb 27, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Feb 27, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 27, 2025 | 8-K | Current Report |
| Feb 27, 2025 | 10-K | Annual Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |